Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

Antibody affinity maturation is a critical step in development of functional antiviral immunity; however, accurate measurement of affinity maturation of polyclonal serum antibody responses to particulate antigens such as virions is challenging. We describe a novel avidity assay employing biolayer interferometry and dengue virus-like particles. After validation using anti-dengue monoclonal antibodies, the assay was used to assess avidity of antibody responses to a tetravalent dengue vaccine candidate (TAK-003) in children, adolescents, and adults during two phase 2 clinical trials conducted in dengue-endemic regions. Vaccination increased avidity index and avidity remained high through 1 year postvaccination. Neutralizing antibody titers and avidity index did not correlate overall; however, a correlation was observed between neutralizing antibody titer and avidity index in those subjects with the highest degree of antibody affinity maturation. Therefore, vaccination with TAK-003 stimulates polyclonal affinity maturation and functional antibody responses, including neutralizing antibodies. To assess antibody affinity maturation, a novel dengue virus avidity assay was developed employing biolayer interferometry and dengue virus-like particles. Vaccination with tetravalent dengue vaccine candidate (TAK-003) increased avidity index, which remained high throughout 1 year.

Automated summary

A novel avidity assay using biolayer interferometry and dengue virus-like particles was developed to assess antibody affinity maturation. Vaccination with tetravalent dengue vaccine candidate (TAK-003) increased avidity index, which remained high throughout 1 year postvaccination.